SOPHiA GENETICS (NASDAQ:SOPH) Announces Earnings Results, Misses Estimates By $0.08 EPS

SOPHiA GENETICS (NASDAQ:SOPH) issued its earnings results on Tuesday. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08), FiscalAI reports. The firm had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative net margin of 41.13% and a negative return on equity of 37.75%.

SOPHiA GENETICS Stock Up 2.7%

Shares of SOPHiA GENETICS stock opened at $4.62 on Tuesday. The firm has a market cap of $312.22 million, a PE ratio of -10.04 and a beta of 1.13. The business’s 50 day simple moving average is $4.93 and its 200 day simple moving average is $4.43. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.62 and a current ratio of 2.80. SOPHiA GENETICS has a 52-week low of $2.58 and a 52-week high of $5.70.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Guggenheim boosted their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, BTIG Research raised their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.00.

Institutional Trading of SOPHiA GENETICS

A number of institutional investors have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. Federated Hermes Inc. lifted its position in SOPHiA GENETICS by 16.4% during the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock worth $682,000 after buying an additional 31,000 shares in the last quarter. Akre Capital Management LLC lifted its position in SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after buying an additional 6,205 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at about $49,000. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.